Kilitch Drugs (India) Limited KILITCH.NS Stock
Kilitch Drugs (India) Limited Price Chart
Kilitch Drugs (India) Limited KILITCH.NS Financial and Trading Overview
Kilitch Drugs (India) Limited stock price | 354.9 INR |
Previous Close | 201.2 INR |
Open | 200.1 INR |
Bid | 202.5 INR x 0 |
Ask | 203.4 INR x 0 |
Day's Range | 200 - 203.9 INR |
52 Week Range | 125 - 231.85 INR |
Volume | 1.46K INR |
Avg. Volume | 29.62K INR |
Market Cap | 3.16B INR |
Beta (5Y Monthly) | 0.369178 |
PE Ratio (TTM) | 30.13393 |
EPS (TTM) | 9.22 INR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | September 20, 2019 |
1y Target Est | N/A |
KILITCH.NS Valuation Measures
Enterprise Value | 2.79B INR |
Trailing P/E | 30.13393 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 2.2603426 |
Price/Book (mrq) | 2.0787354 |
Enterprise Value/Revenue | 2 |
Enterprise Value/EBITDA | 15.892 |
Trading Information
Kilitch Drugs (India) Limited Stock Price History
Beta (5Y Monthly) | 0.369178 |
52-Week Change | 26.30% |
S&P500 52-Week Change | 20.43% |
52 Week High | 231.85 INR |
52 Week Low | 125 INR |
50-Day Moving Average | 193.48 INR |
200-Day Moving Average | 167.08 INR |
KILITCH.NS Share Statistics
Avg. Volume (3 month) | 29.62K INR |
Avg. Daily Volume (10-Days) | 6.84K INR |
Shares Outstanding | 15.58M |
Float | 2.31M |
Short Ratio | N/A |
% Held by Insiders | 72.82% |
% Held by Institutions | 0% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | March 31, 2023 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | March 31, 2024 |
Profitability
Profit Margin | 7.48% |
Operating Margin (ttm) | 10.04% |
Gross Margin | 46.44% |
EBITDA Margin | 12.58% |
Management Effectiveness
Return on Assets (ttm) | 4.07% |
Return on Equity (ttm) | 5.69% |
Income Statement
Revenue (ttm) | 1.4B INR |
Revenue Per Share (ttm) | 89.65 INR |
Quarterly Revenue Growth (yoy) | 24.19% |
Gross Profit (ttm) | 677.58M INR |
EBITDA | 175.66M INR |
Net Income Avi to Common (ttm) | 104.48M INR |
Diluted EPS (ttm) | 6.72 |
Quarterly Earnings Growth (yoy) | 23.00% |
Balance Sheet
Total Cash (mrq) | 591.77M INR |
Total Cash Per Share (mrq) | 38.03 INR |
Total Debt (mrq) | 221.94M INR |
Total Debt/Equity (mrq) | 14.74 INR |
Current Ratio (mrq) | 1.835 |
Book Value Per Share (mrq) | 97.415 |
Cash Flow Statement
Operating Cash Flow (ttm) | 25.86M INR |
Levered Free Cash Flow (ttm) | -38863124 INR |
Profile of Kilitch Drugs (India) Limited
Country | India |
State | N/A |
City | Mumbai |
Address | 37/39, Ujagar Industrial Estate |
ZIP | 400088 |
Phone | 91 22 6121 4100 |
Website | https://www.kilitch.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, non-steroidal anti-inflammatory, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products in the form of ampoules, vials, and dry powder injectables. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, capsules, dry syrup, gripe water, and oral powder and liquid in the antibiotic, anti-diabetics, cardiovascular, and other areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, ROIVIT, and PH-7; and various nutritional products, such as CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, lotions, liquids, creams, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.
Q&A For Kilitch Drugs (India) Limited Stock
What is a current KILITCH.NS stock price?
Kilitch Drugs (India) Limited KILITCH.NS stock price today per share is 354.9 INR.
How to purchase Kilitch Drugs (India) Limited stock?
You can buy KILITCH.NS shares on the NSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Kilitch Drugs (India) Limited?
The stock symbol or ticker of Kilitch Drugs (India) Limited is KILITCH.NS.
Which industry does the Kilitch Drugs (India) Limited company belong to?
The Kilitch Drugs (India) Limited industry is Drug Manufacturers-Specialty & Generic.
How many shares does Kilitch Drugs (India) Limited have in circulation?
The max supply of Kilitch Drugs (India) Limited shares is 16.15M.
What is Kilitch Drugs (India) Limited Price to Earnings Ratio (PE Ratio)?
Kilitch Drugs (India) Limited PE Ratio is 38.49240500 now.
What was Kilitch Drugs (India) Limited earnings per share over the trailing 12 months (TTM)?
Kilitch Drugs (India) Limited EPS is 9.22 INR over the trailing 12 months.
Which sector does the Kilitch Drugs (India) Limited company belong to?
The Kilitch Drugs (India) Limited sector is Healthcare.